Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO renews urgent call for global investment in TB (tuberculosis):

This article was originally published in Clinica

Executive Summary

The World Health Organization (WHO) has renewed calls for a global concerted effort to tackle tuberculosis, after a study revealed a huge rise in multidrug-resistance (MDR-TB), highlighting the need to tighten monitoring of the disease. Eastern Europe and central Asia have emerged as hotspots of the problem, associated with high HIV rates (some 1.5 million people, compared with some 30,000 in 1995). The Commonwealth of Independent States is worst affected, with MDR-TB rates of up to 14%. Mapping of the situation in six of China's 23 provinces revealed rates of around 10% in at least two. The WHO estimates that there are around 300,000 new cases of MDR-TB a year. Investment in global TB prevention - which includes diagnostic and therapy-monitoring testing - is the only way of reducing TB incidence and containing it geographically, says the WHO.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057749

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel